BRAF and non-small cell lung carcinoma: Some resistance mechanisms may be overcome by novel multi-RAF and downstream ERK1/2 inhibitors, like LXH254 and LTT462, which are in early phase trials for BRAF or KRAS mutant NSCLC [188].